IL2 and neoplasm: Without genetic modification, ACT with TILs (TIL-ACT) first extracts the infiltrating lymphocytes from the patients’ tumor tissues through biopsy or surgery, and then expand them in vitro with IL-2 stimulation, followed by infusion of TILs back into the same patients for treatment.